Ad is loading...
ESCGX
Price
$10.31
Change
-$0.07 (-0.67%)
Updated
Nov 15 closing price
RNWHX
Price
$79.27
Change
-$0.78 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

ESCGX vs RNWHX

Header iconESCGX vs RNWHX Comparison
Open Charts ESCGX vs RNWHXBanner chart's image
Ashmore Emerging Markets Equity ESG C
Price$10.31
Change-$0.07 (-0.67%)
VolumeN/A
CapitalizationN/A
American Funds New World R5E
Price$79.27
Change-$0.78 (-0.97%)
VolumeN/A
CapitalizationN/A
ESCGX vs RNWHX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ESCGX vs. RNWHX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESCGX is a StrongSell and RNWHX is a Buy.

FUNDAMENTALS
Fundamentals
RNWHX has more cash in the bank: 60.9B vs. ESCGX (12.5M). RNWHX pays higher dividends than ESCGX: RNWHX (1.44) vs ESCGX (0.03). ESCGX was incepted earlier than RNWHX: ESCGX (5 years) vs RNWHX (9 years). ESCGX is a more actively managed with annual turnover of: 51.00 vs. RNWHX (32.00). RNWHX has a lower initial minimum investment than ESCGX: RNWHX (250) vs ESCGX (1000). ESCGX annual gain was more profitable for investors over the last year : 12.92 vs. RNWHX (11.41).
ESCGXRNWHXESCGX / RNWHX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years9 years-
Gain YTD8.0717.006115%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets12.5M60.9B0%
Annual Yield % from dividends0.031.442%
Returns for 1 year12.9211.41113%
Returns for 3 years-30.54-14.83206%
Returns for 5 yearsN/A16.60-
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RDCM11.610.61
+5.55%
Radcom Ltd
CBL27.26-0.03
-0.11%
CBL & Associates Properties
FLEX37.20-0.44
-1.17%
Flex Ltd
CPOP1.19-0.08
-6.30%
Pop Culture Group Co Ltd
DYN28.39-1.92
-6.33%
Dyne Therapeutics